Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-HER2 CAR-T in HER2-positive Advanced Solid Tumors
NCT06658951Phase 2Recruiting
- Sponsor
- UTC Therapeutics
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-HER2 CAR-T cells in breast cancer, sponsored by UTC Therapeutics. Started Apr 2025; status: recruiting.
02
Drugs
anti-HER2 CAR-T cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06658951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658951.